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Abstract
Background: Full RNA-Seq is a fundamental research tool for whole transcriptome analysis. However, it is too
costly and time consuming to be used in routine clinical practice. We evaluated the transcript quantification
agreement between RNA-Seq and a digital multiplexed gene expression platform, and the subtype call after
running the PAM50 assay in a series of breast cancer patients classified as triple negative by IHC/FISH. The goal of
this study is to analyze the concordance between both expression platforms overall, and for calling PAM50 triple
negative breast cancer intrinsic subtypes in particular.
Results: The analyses were performed in paraffin-embedded tissues from 96 patients recruited in a multicenter,
prospective, non-randomized neoadjuvant triple negative breast cancer trial (NCT01560663). Pre-treatment core
biopsies were obtained following clinical practice guidelines and conserved as FFPE for further RNA extraction.
PAM50 was performed on both digital multiplexed gene expression and RNA-Seq platforms. Subtype assignment
was based on the nearest centroid classification following this procedure for both platforms and it was concordant
on 96% of the cases (N = 96). In four cases, digital multiplexed gene expression analysis and RNA-Seq were
discordant. The Spearman correlation to each of the centroids and the risk of recurrence were above 0.89 in both
platforms while the agreement on Proliferation Score reached up to 0.97. In addition, 82% of the individual PAM50
genes showed a correlation coefficient > 0.80.
Conclusions: In our analysis, the subtype calling in most of the samples was concordant in both platforms and the
potential discordances had reduced clinical implications in terms of prognosis. If speed and cost are the main
driving forces then the preferred technique is the digital multiplexed platform, while if whole genome patterns and
subtype are the driving forces, then RNA-Seq is the preferred method.
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Background
Gene expression signatures are becoming a key tool for
decision-making in oncology, and especially in breast can-
cer. In 2000, Perou et al. identified 4 intrinsic subtypes of
breast cancer with clinical implications from microarray
gene expression data: Luminal A (LumA), Luminal B
(LumB), HER2-enriched and Basal-like [1–3]. These breast
cancer subtypes yielded a superior prognostic impact than
classical immunohistochemistry (IHC) factors. Almost a
decade later Parker et al. developed from the initial intrinsic
subtypes, a 50-gene signature for subtype assignment [4].
Initially developed on microarray data, PAM50 is being
successfully used in digital multiplexed gene expression
platforms such as NanoString nCounter®, which is the basis
for the Prosigna® test. The latter includes the PAM50 assay
in combination with a clinical factor (i.e. tumor size) and
has been approved for the risk of distant relapse estimation
in postmenopausal women with hormone receptor-
positive, node negative or node positive early stage breast
cancer patients; and is a daily-used tool assessing the indi-
cation of adjuvant chemotherapy [5, 6].
The NanoString nCounter® system enables gene expres-
sion analysis through direct multiplexed measurements.
This technology is based on 2 probes specific to each gene
of interest, a capture probe and a reporter probe, consist-
ing of a complementary sequence to the target messenger
RNA (mRNA) coupled to a color-coded tag [7]. Unique
pairs of capture and reporter probes are designed for each
gene of interest, and up to 800 genes can be analyzed sim-
ultaneously for a single sample. Tumor RNA and probes
are hybridized together and following purification and
alignment, they are identified and quantified by the
analyzer. NanoString has proved to be highly reprodu-
cible, and has shown a high concordance between fresh-
frozen (FF) and formalin-fixed paraffin-embedded (FFPE)
derived RNAs [8].
On the other hand, RNA-Seq has become the corner-
stone of modern whole transcriptome analyses. It repre-
sents a useful tool for discovery and validation of
biomarkers. The use of FFPE has been a concern in the
past but several studies observed that this kind of samples
are suitable to be used in RNA-Seq platforms assessing for
gene expression analyses, and comparable to fresh frozen
tissue [9]. From the technical point of view, typical RNA-
Seq protocols based on poly(A) enrichment of the mRNA
in order to remove ribosomal RNA, fail to capture the
partially degraded mRNA in FFPE samples. However this
limitation can be overcome by using Ribo-Zero-Seq and it
has been proved that it performs as good as microarrays
or RNA-Seq based on poly(A) enrichment [10]. However,
its processing time requirements and economic costs
make it difficult its implementation in daily clinical prac-
tice scenario. In this study, we compared the performance
of the intrinsic subtype determination by PAM50 along
with the risk of recurrence (ROR) estimation from both
platforms: RNA-Seq and NanoString nCounter®, by using
the same samples on both and directly comparing results.
Results
Sample quality
Overall, 96 samples were successfully processed and had
sufficient RNA for both NanoString nCounter® and
RNA-Seq transcript quantification. The mean RNA con-
centration from the FFPE samples was 146.9 ng/μl, mean
RNA integrity number (RIN) value was 2.015 (min/max:
1.1/3.7; 95% CI: 1.899–2.130) and its mean A260/A280
ratio was 1.98 (min/max: 1.83/2.06; 95% CI: 1.971–
1.979) (Additional file 2: Table S2, online only). None of
the samples used in RNA-Seq had measurable amounts
of rRNA and all the samples presented optimal metrics.
Moreover, the none of the samples processed in Nano-
String nCounter® presented technical issues and just
three of them presented negligible control/count hints.
Both quality control (QC) reports are in the respective
Additional files 4 and 5 (online only).
Intrinsic subtype calling
The intrinsic subtype calling results in both RNA-Seq
and NanoString nCounter® are shown in the Additional
file 1: Table S1 (online only).
As displayed in Fig. 1, NanoString nCounter® classified
84.3% of the patients as Basal-like, 11.5% as HER2-
enriched, 3.1% as LumA and 1.0% as LumB. RNA-Seq in-
trinsic subtype distribution was as follows: 78.1% basal-
like, 16.7% HER2-enriched, 4.2% LumA, 1.0% LumB.
As displayed in Table 1, we had 7 patients with dis-
cordant subtype calls by the two techniques (7.3%).
However, we observed that 3 patients had their second
closest centroids within a distance ≤0.10 (range: 0.01 to
0.10), one of them concordant with the call offered by
the other technique. The remaining 4 discordant cases
showed real discordances in their calls and centroids
proximity. Taking this information into account, we con-
sidered that subtype calling agreed on 96% of the cases
(NanoString nCounter®/RNA-Seq discordances: 3 Basal-
like/HER2-enriched and 1 HER2-enriched/LumA). We
reevaluated the discordant samples in the PAM50 assay
output. We only observed that one sample (HUGM-
0022) had a low confidence score (0.42) in RNA-Seq due
to extremely similar centroid correlation values, thus we
really cannot classify it with a high degree of confidence.
PAM50 centroids and risk of recurrence
We next analyzed the correlation to each of the centroids
obtained through NanoString nCounter® and RNA-Seq
data, and we observed that the Spearman’s rho was above
0.95 for all the centroids (Basal-like/HER2-enriched 0.97,
LumA 0.95, and LumB 0.96) (Fig. 2).
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In addition, we evaluated the correlation between
each of the different centroids for both platforms and
we observed similar results. The highest positive cor-
relation was for the HER2-enriched and LumB
centroids, with a Spearman’s rho of 0.83 and 0.85
(p < 0.01) with RNA-Seq and NanoString nCounter®,
respectively. On the other hand, Basal-like and LumA
centroids had the strongest inverse correlation (rho
0.86 and 0.76, p < 0.01 with RNA-Seq and NanoString
nCounter®, respectively) (Fig. 3).
Fig. 1 PAM50 subtype calls by technique. Barplot represents counts of samples per subtype and technique. The cross table shows in detail the
discordances between both platforms
Table 1 Centroid correlation for the potential discordant sample calls
These measures are extracted from the PAM50 assay outcome (Additional file 1: Table S1). The sample’s subtype classification is assigned to the centroid with the
highest correlation (in bold red). When the second centroid has a value close to the highest one (difference less or equal to 0.1) the classification is ambiguous
being possible any of both subtypes (bold *). The Discordance column summarizes whether a real discordance is observed in a sample or just a scenario where
two centroid correlations are almost equivalent (HUGM-0047 in NanoString nCounter® is a paradigmatic case)
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The risk of recurrence score (ROR), and considering
the role of the Proliferation Score (ROR + PS), had a
Spearman’s rho of 0.90 and 0.97, respectively. Thus, in
terms of ROR, the results show an extremely high corre-
lated scenario. We observed high agreement between
techniques in the Bland-Altman plots displayed in Fig. 4,
as most of the differences remain close to the null base-
line level within the confidence interval. In addition, the
intraclass correlation coefficient (ICC) for ROR reached
0.93 [0.89–0.95] and ROR + PS reached 0.96 [0.94–0.97].
Additional measures such as expression level of HER2,
along with the Proliferation Score, also showed a high
degree of correlation between both platforms with a
Spearman’s rho 0.96 and 0.97, respectively.
Individual gene correlation
We lastly evaluated the correlation coefficients for each
of the 50 genes in the PAM50 gene list. We measured
the expression levels in log2 scale in both platforms. We
observed that in our dataset 23 genes had a correlation
greater than 0.9, 18 genes between 0.8 and 0.9, 7 genes
between 0.7 and 0.8 and only 2 genes had a correlation
lower than 0.7. The median ICC was 0.90 (mean = 0.88)
(Fig. 5 and Additional file 3: Table S3, online only).
Discussion
The goal of the study was assessing the reproducibility of
PAM50 intrinsic subtype when using RNA-Seq and Nano-
String nCounter® data from FFPE tissue obtained from a
triple negative breast cancer (TNBC) patient cohort. We
noticed that the PAM50 subtype calling was concordant
on 96% of the cases and the expression in genes that com-
prise the PAM50 assay had a median ICC of 0.90.
PAM50 was originally developed and validated using
microarray data from 1753 genes, but since then it has
been transferred into a wide variety of platforms. Inter-
estingly, PAM50 performance has been evaluated by
comparing quantitative real-time reverse-transcription-
PCR (qRT-PCR) and NanoString nCounter® [11]. That
study obtained an overall concordance of 0.94 in subtype
Fig. 2 Separate centroid correlation when NanoString nCounter® and RNA-Seq platforms are compared. The blue line represents the linear
regression. The grey area surrounding it represents the confidence interval
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Fig. 3 Correlation of the correlation to the centroids in both platforms obtained in the PAM50 subtype classifier
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calls, 0.98 for ROR and 0.95 for ROR + PS. Regarding in-
dividual gene expression, median ICC was 0.90 [11].
These measures are very similar to ours comparing
NanoString nCounter® and RNA-Seq, as we presented in
the Results Section.
In this TNBC cohort 4 samples out of 96 were misclassi-
fied in the subtype calling. While this might be concerning
from the patient care perspective, it is strongly suggested in
these cases to evaluate the ROR and ROR+ PS, because
from the clinical point of view the ROR-score group is
more important to select therapy (chemotherapy vs no
chemotherapy) than the plain subtype calling. The PAM50
assay provides numeric and categorical values for both
scores and we observed in the misclassified samples the
assigned risk group remained the same except in one pa-
tient with discordant low/medium ROR (Table 2).
Perou, Sørlie, Hu, Nielsen et al. evaluated the prognostic
effect of PAM50 genes using the qRT-PCR from FFPE sam-
ples, and demonstrated its superiority to standard clinico-
pathological factors in predicting long-term survival of
estrogen receptor positive tumors [12, 13]. There is signifi-
cant evidence that IHC is not a reliable surrogate of
genomic intrinsic subtype, and that gene expression
methods have a higher predictive and prognostic value than
IHC [12, 14, 15]. Moreover, in a comprehensive review in
breast cancer gene-expression based assays by Prat et al. it
is shown that the concordance between two different ER/
PR testing methods based on IHC falls below the highest
levels of reproducibility/concordance expected in daily clin-
ical use [16].
The kind of samples to be processed is often a major
factor in deciding which technology should be used to
quantify transcripts and perform the PAM50 assay. In
medical research the FFPE are the most common sources
of archived material because they are cheap, easy to
process and stable for a very long time. The PAM50 PCR-
based classifier has been validated and translated into the
NanoString nCounter® platform, because it previously
demonstrated higher performance than PCR for FFPE
data [8]. Since this platform does not require an amplifica-
tion step, it enables a more sensitive analysis of degraded
mRNA from FFPE samples [17, 18]. Although it seems
that NanoString and DNA microarrays show a good cor-
relation, similar to the one found when comparing distinct
Fig. 4 Correlation of ROR and ROR + PS and their associated Bland-Altman plots in both platforms. The upper/lower dashed lines in the Bland-
Altman plots represent the mean difference +/− 1.96 * standard deviation. The central dashed line represents the mean difference
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Fig. 5 Normalized gene expression levels for each gene contained in the PAM50 assay. The log2 normalized counts for RNA-Seq are represented
in the X-axis and those for NanoString nCounter® are represented in the Y-axis. The red line represents the LOWESS smoother, which uses locally
weighted polynomial regression
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microarrays platforms [7], correlations between FF micro-
arrays and FFPE was moderate due to RNA poor quality
in the FFPE samples. According to Chen et al. NanoString
detected a higher number of transcripts than microarrays
(88.4% vs. 82.6%) [17].
Several studies for both oncologic and non-oncologic
diseases have shown a good correlation between gene
expression data from RNA-Seq and NanoString nCoun-
ter® (R2 = 0.90 for FFPE samples in idiopathic pulmonary
fibrosis) [19]. Particularly in breast cancer, NanoString
nCounter® and RNA-Seq using Illumina TruSeq Ribo-
Zero-Gold RNA-Seq enable reliable gene expression
analysis from degraded FFPE RNA. This study encour-
ages the role of NanoString nCounter® as a validation
platform from data discovered by RNA-Seq, with a high
reproducibility of both techniques (R2 = 0.99 for tech-
nical replicates), high correlation with FF matched sam-
ples (R2 = 0.874 for NanoString) and a high correlation
between both platforms (R2 = 0.838) [8].
While RNA-Seq technologies can be used in multiple re-
search scenarios [20] a digital multiplexed platform pro-
vides several advantages over RNA-Seq technologies in
daily clinical practice in terms of cost, amount of needed
RNA, computational cost and the use of FFPE samples.
This last factor is often crucial in clinical research as fresh
frozen (FF) tissue is generally unavailable due to the infra-
structure and timing required, making it difficult to reach
the necessary number of samples in multicenter studies.
However, that means increased sequencing costs in order
to get enough reads to achieve adequate coverage of coding
genes. In this project the estimated full cost for processing
and sequencing an RNA-Seq sample was around 800–1000
USD; on the other hand, the cost of processing a sample in
NanoString nCounter® was just around 190 USD. The over-
all financial burden to perform PAM50 using NanoString
nCounter® in a diagnostic laboratory is lower than any
RNA-Seq option in terms of equipment and experts, as the
latter may require outsourcing the analyses. This situation
usually entails longer delivery times as long as the sample
processing and transcript quantification using NanoString
nCounter® can be achieved in less than 28 h. In addition,
the amount of RNA needed in both platforms is substan-
tially different: in our case we ran the analyses using 500–
1000 ng in RNA-Seq and only 250 ng in NanoString
nCounter®; the latter claims to keep its performance with
only 125 ng. Additionally, the computational costs can be
several orders of magnitude higher in processing RNA-Seq
than NanoString nCounter® samples because the former
needs computationally demanding processes of alignment
and transcript quantification.
Finally, our study shows that PAM50 intrinsic subtype
in TNBC patients, which are mostly basal-like, is repro-
ducible between different platforms. This encourages the
solidity of the classification. Moreover, our comparison
comes from the same FFPE-extracted RNA, directly
comparing the platform with no RNA quality bias.
Conclusions
The PAM50 subtype calling agreement between RNA-Seq
and NanoString nCounter® transcript quantification tech-
nologies was evaluated in FFPE tissue samples obtained
from a TNBC patient cohort. We observed that the subtype
Table 2 Risk of Recurrence (ROR) for the potential discordant sample calls
Sample ID ROR ROR-Group ROR-PS ROR + PS-Group Discordance
NanoString nCounter HCSC-0027 51.10 med 43.42 med NO
HLPR-002 43.57 med 23.44 med YES
HUGM-0022 51.60 med 42.28 med NO
HUGM-0029 73.51 high 68.98 high NO
HUGM-0047 81.24 high 72.48 high NO
INEN-0017 66.66 high 55.051 high NO
INEN-0021 72.50 high 65.40 high NO
RNA-Seq HCSC-0027 35.25 med 33.04 med NO
HLPR-002 16.87 low 10.68 low YES
HUGM-0022 40.68 med 32.44 med NO
HUGM-0029 75.02 high 69.59 high NO
HUGM-0047 73.73 high 69.58 high NO
INEN-0017 62.68 high 52.98 high NO
INEN-0021 66.98 high 64.52 high NO
These measures are extracted from the PAM50 assay outcome (Additional file 1: Table S1). Two measures regarding the risk of recurrence are reported: ROR,
which takes into account only the subtype calling; and ROR + PS, which considers also the Proliferation Score. The latter is defined as the mean expression level
for the proliferation genes: CCNB1, UBE2C, BIRC5, KNTC2, CDC20, PTTG1, RRM2, MKI67, TYMS, CEP55 and CDCA1. The ROR(+PS)-Group columns gives a categorical
classification in terms of risk: high, medium (med) and low
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call was concordant in most of the samples and the poten-
tial discordances had reduced clinical implications in terms
of prognosis. Although PAM50 can be used with RNA-Seq
data and it shows similar results to NanoString nCounter®;
the former is still difficult to use in daily clinical practice
due to its processing time requirements and economic
costs, unlike the discussed digital multiplexed option.
Methods
Patients and samples
The analyses were performed in FFPE samples from 96
patients recruited in a previously described multicenter,
prospective, non-randomized neoadjuvant TNBC trial
(NCT01560663) [21]. This cohort consisted of early stage
TNBC patients, defined as estrogen and progesterone re-
ceptor (ER and PR) < 1% and HER2-negative according to
the ASCO-CAP guidelines, candidate for neoadjuvant
treatment with carboplatin and docetaxel [22, 23].
This trial included patients from 7 centers across Spain
and Peru. Pre-treatment core biopsies were performed
and conserved as FFPE following each institution protocol
for further RNA extraction.
This study was reviewed and approved by the Ethical
Board at all the participating institutions, and all patients
included were required to sign a written informed con-
sent. All clinical data and samples were anonymized.
RNA extraction
FFPE blocks were centralized and included in a biologic
sample bank at the Translational Oncology Laboratory
(LAOT), which belongs to the Medical Oncology De-
partment at the Hospital General Universitario Gregorio
Marañón, registered at the Instituto de Salud Carlos III;
in Madrid, Spain.
RNA extraction and PAM50 intrinsic subtyping on the
nCounter® platform were performed at the LAOT. Inva-
sive tumor from haematoxilin and eosin stained slides
was delimited by a pathologist at the LAOT and was
subsequently microdissected in 10 μm slides. The num-
ber of slides recommended based on the measured
tumor surface area on the hematoxylin and eosin (H&E)
stained slide; 4-19 mm2: 6 unstained 10 μm slides; 20–
99mm2: 3 unstained 10 μm slides; ≥100 mm2: 1 un-
stained 10 μm slide. RNA was then extracted using the
RNeasy FFPE Kit (Qiagen), which is specially designed
for purification of total RNA from FFPE tissue sections
by isolating RNA molecules longer than 70 nucleotides.
Firstly, all paraffin is removed from freshly cut FFPE tis-
sue sections by treating with deparaffinization solution
or using an alternative deparaffinization method. Next,
samples are incubated in an optimized lysis buffer, which
contains proteinase K, to release RNA from the sections.
A short incubation at a higher temperature partially re-
verses formalin crosslinking of the released nucleic acids,
improving RNA yield and quality, as well as RNA per-
formance in downstream enzymatic assays. This is
followed by DNase treatment that is optimized to elim-
inate all genomic DNA, including very small DNA frag-
ments that are often present in FFPE samples after
prolonged formalin fixation and/or long storage times.
Next, the lysate is mixed with Buffer RBC. Ethanol is
added to provide appropriate binding conditions for RNA,
and the sample is then applied to a RNeasy MinElute spin
column, where the total RNA binds to the membrane and
contaminants are efficiently washed away. RNA is then
eluted in a minimum of 14 μl of RNase-free water. RNA
concentration and quality were assessed with Nanodrop
2000 Spectophotometer (Thermo Scientific NanoDrop
Products) according to A260/280 ratio. RIN was evaluated
with the TapeStation 2200 (Agilent Technologies, Germany)
.
NanoString nCounter®
From an initial panel of 110 genes, we analyzed the ex-
pression of the 50 genes included in the PAM50 assay
and 5 additional housekeeper genes described by Parker
et al [4]. In the raw nCounter® transcript quantification
the background was corrected using the negative
probes and normalized with their mean minus 2 stand-
ard deviations, and those values were normalized by
calculating the geometric mean of the 5 housekeeper
genes. Subtype classification was assigned based on the
nearest of the 5 centroids.
RNA-Seq
Sequencing was performed at the University of North
Carolina (UNC) at Chapel Hill (NC, US). 300-1000 ng of
total FFPE RNA was used to create an RNA-Seq library
using the Illumina TruSeq Ribo-Zero Gold Kit (RS - 1
22–2301 or RS - 122 - 2302). Libraries were then se-
quenced 2 per lane on a HiSeq2500 with 48x7x48 bp
configuration. Alignment against GRCh37 and transcript
quantification was done using MapSplice [23] v2.2.1 and
RSEM [4] v1.3.0 using the UCSC GAF2.1 KnownGenes
using UBU v1.0 (https://github.com/mozack/ubu), re-
spectively. Samples were normalized to a fixed upper
quartile (1000 genes) followed by log2 transformation.
The PAM50 algorithm was run according to the scripts
provided by Parker et al [4] adjusting the genes to a pre-
viously determined estrogen receptor balanced median
from FFPE samples assayed by TruSeq Ribo-Zero Gold
to adjust samples to match the training set. The code
and median adjustment value are provided as Additional
file 6.
Quality control analysis
The quality control for the RNA-Seq samples was assessed
using the .fastq files in FastQC v0.11.8 [24]. We also
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evaluated the potential presence of ribosomal RNA se-
quences obtained from the UCSC Genome Browser [25]
using FastQ Screen v0.13.0 [26]. The QC for the Nano-
String nCounter® samples was done using NanoStringQC-
Pro [27].
Statistical analysis
We used R [28] v3.3.3 in order to evaluate the transcript
quantification in both platforms, and the PAM50 sub-
type calling along with its associated centroid values and
the ROR. All comparisons between continuous variables
were performed using the Spearman correlation. The
inter-rater agreement analysis for molecular subtype
classification was based on the Cohen’s kappa calcula-
tion. For continuous variables ICC two way mixed effect
single measures [29] was calculated. Given ROR import-
ance in diagnostic, a Bland-Altman plot was constructed
to further assess agreement between platforms.
Additional files
Additional file 1: Table S1. PAM50 output for RNA-Seq and NanoString
nCounter. PAM50 table of results for RNA-Seq and NanoString nCounter®.
It is reported for each sample and platform: the centroid correlation, the
subtype call with its confidence, the ROR and ROR + PS values and
groups, the Proliferation Score; and the ER/HER2 gene expression. (XLSX
90 kb)
Additional file 2: Table S2. RNA Sample Quality Control. The RNA
concentration measured in each sample, absorbance values for A260 and
A280, the A260/A280 ratio and the measured RIN. Descriptive statistics
are provided for A260/A280 ratio and RIN. (XLSX 16 kb)
Additional file 3: Table S3. PAM50 genes correlation and inter-rate
agreement analyses. Correlation analysis using the Spearman’s rho where
the gene expression measured in RNA-Seq and NanoString nCounter®
are compared. The inter-rater agreement analysis for the PAM50 genes
was based on the Cohen’s kappa calculation using two-way mixed effect
single measures. The statistics and p-values are provided in both analyses.
(XLSX 17 kb)
Additional file 4: QC – Fastq. RNA-Seq data Quality Control. FastQC and
FastQ Screen reports summarized using MultiQC. All the information is
summarized in an interactive .html. Additionally, a table is provided to as-
sociate the sample IDs mentioned in the manuscript with the IDs gener-
ated during the sequencing process. (ZIP 5962 kb)
Additional file 5: QC – NanoString. NanoString nCounter data Quality
Control. NanoStringQCPro reports in .html files. Technical, control and
count-based metrics are reported. Additionally, a table is provided to as-
sociate the sample IDs mentioned in the manuscript with the IDs gener-
ated during the NanoString nCounter® quantification process. (ZIP 15743
kb)
Additional file 6: Code. Normalization and PAM50 scripts for both
platforms. Scripts used to perform the PAM50 assay in RNA-Seq and
NanoString nCounter® platforms, along with additional technique-specific
and transcript ID files. (ZIP 91 kb)
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